Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hebei Medical Univ. HDAC6 compound 4u
- Development stage
- Unknown
- Lead developer
- Hebei Medical University
01
Overview
Hebei Medical Univ. HDAC6 compound 4u: sourced facts only. name: "Furthermore, 4u selectively inhibits HDAC6 activity, as validated by the strong binding affinity observed between 4u and HDAC6." [PMID:42061097]; target: "Furthermore, 4u selectively inhibits HDAC6 activity, as validated by the strong binding affinity observed between 4u and HDAC6." [PMID:42061097]; developer: "School of Pharmaceutical Sciences, Hebei Medical University, 050017 Shijiazhuang, China." [PMID:42061097]; stage: "Furthermore, in vitro results were validated by in vivo assays, showing that 4u could inhibit tumor growth and HDAC6 activity in an animal model." [PMID:42061097]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Hebei Medical Univ. HDAC6 compound 4u.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hebei Medical Univ. HDAC6 compound 4u.